References
- Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, Araki S, Mori M, Nagataki S, Matsukura S, Akamine T, Nakagawa M, Yamamoto I, Osame M. Interferon-alpha is effective in HTLV- I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 1996; 46: 1016–1021
- Matsuzaki T, Nakagawa M, Nagai M, Usuku K, Higuchi I, Arimura K, Kubota H, Izumo S, Akiba S, Osame M. HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: Analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J NeuroVirol 2001; 7: 228–234
- Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, Hashiguchi S, Ichinose M, Bangham C R, Izumo S, Osame M. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J NeuroVirol 1998; 4: 586–593
- Nakagawa M, Higashi K, Matsuzaki T, Saito M. Prognosis of 314 patients with HAM and HTLV-I proviral load. Sogo Rinsho 2004; 53: 2103–2110
- Nakagawa M, Izumo S, Ijichi S, Kubota H, Arimura K, Kawabata M, Osame M. HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J NeuroVirol 1995; 1: 50–61
- Nakagawa M, Nakahara K, Maruyama Y, Kawabata M, Higuchi I, Kubota H, Izumo S, Arimura K, Osame M. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. J NeuroVirol 1996; 2: 345–355
- Osame M. Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. Human retrovirology: HTLV, W A Blattner. Raven Press, New York 1990; 191–197
- Osame M, Matsumoto M, Usuku K, Izumo S, Ijichi N, Amitani H, Tara M, Igata A. Chronic progressive myelopathy associated with elevated antibodies to HTLV-I and adult T-cell leukemia-like cells. Ann Neurol 1987; 21: 117–122
- Osame M, McArthur J C. Neurological manifestations of infection with human T cell lymphotropic virus type I. Diseases of the nervous system: clinical neurobiology, 2nd ed., A K Asbury, et al. WB Saunders, Philadelphia 1992; vol 2: 1331–1339
- Saito M, Nakagawa M, Kaseda S, Matsuzaki T, Jonosono M, Eiraku N, Kubota R, Takenouchi N, Nagai M, Furukawa Y, Usuku K, Izumo S, Osame M. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-a therapy for HTLV-I–associated myelopathy/tropical spastic paraparesis. J Infect Dis 2004; 189: 29–40
- Thierry V, Jacques D. Clinical toxicity of the interferons. Drug Safety 1994; 10: 115–150
- Yamasaki K, Kira J, Koyanagi Y, Kawano Y, Miyano-Kurosaki N, Nakamura M, Baba E, Suzuki J, Yamamoto A, Yamamoto N, Kobayashi T. Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study. J Neurol Sci 1997; 147: 135–144